SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

11 Nov 2022 Evaluate
The company's total revenue for the quarter ended September 2022 saw a slight change in the total revenue, having registered a total revenue of Rs. 14848.80 millions.A big decline of -34.88% was reported for the quarter ended September 2022 to Rs. 1677.80  millions from Rs. 2576.40 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 3085.30 millions from 3740.90 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 14848.80 14238.40 4.29 29541.60 29024.40 1.78 53993.60 51391.60 5.06
Other Income 365.90 150.70 142.80 554.00 286.80 93.17 561.30 622.40 -9.82
PBIDT 3085.30 3740.90 -17.53 5847.90 7816.80 -25.19 12996.70 15758.20 -17.52
Interest 90.10 14.70 512.93 158.00 27.30 478.75 72.10 81.40 -11.43
PBDT 2995.20 3726.20 -19.62 5689.90 7789.50 -26.95 12924.60 15676.80 -17.56
Depreciation 549.20 505.00 8.75 1083.30 1004.60 7.83 2041.00 1877.20 8.73
PBT 2446.00 3221.20 -24.07 4606.60 6784.90 -32.11 10883.60 13799.60 -21.13
TAX 768.20 644.80 19.14 1490.60 1361.30 9.50 2174.20 2391.90 -9.10
Deferred Tax 26.70 83.00 -67.83 154.60 174.50 -11.40 201.40 -57.90 -447.84
PAT 1677.80 2576.40 -34.88 3116.00 5423.60 -42.55 8709.40 11407.70 -23.65
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 20.78 26.27 -20.92 19.80 26.93 -26.50 24.07 30.66 -21.50

Ipca Laboratories Share Price

1563.70 19.75 (1.28%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×